Skip to main navigation Skip to search Skip to main content

HBV reactivation and its management in HBV-related HCC patients undergoing HAIC-TKI-ICI therapy: A multicenter study

  • Jiayun Liu
  • , Bo Sun
  • , Jiahua Zou
  • , Xiaolin Zhang
  • , Haitao Li
  • , Hongyao Hu
  • , Hui Zhao
  • , Wei Lu
  • , Xun Ding
  • , Guilin Zhang
  • , Ziqiao Lei
  • , Chuansheng Zheng*
  • , Xuefeng Kan*
  • *Corresponding author for this work
  • Huazhong University of Science & Technology
  • Hubei Prov Clin Res Ctr Precis Radiol & Intervent
  • Hubei Prov Key Lab Mol Imaging
  • Huanggang Cent Hosp
  • China Three Gorges University

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

This study aimed to assess hepatitis B virus (HBV) reactivation, its impact on prognosis, and its management in patients with HBV-related hepatocellular carcinoma (HCC), who received hepatic arterial infusion chemotherapy (HAIC) plus tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), and entecavir (HAIC+TKIs+ICIs+entecavir) treatments. Three hundred and seven patients in five centers with advanced HBV-related HCC, who received the quadruple treatment, were included. The HBV reactivation was observed in 44 (14.3%) patients. HBV-DNA level >= 1 x 10(4) IU/mL, positive HBeAg, and white blood cell count <4 x 10(9)/L were the independent risk factors of HBV reactivation. The median progression-free survival and median overall survival of patients in the HBV non-reactivation group were significantly longer than those of patients in the HBV reactivation group (p < 0.001, p < 0.001). The additional treatment with tenofovir alafenamide fumarate can effectively manage the HBV reactivation and improve the survival of these HBV reactivated HCC patients.
Original languageEnglish
Article number112689
Number of pages11
JournalISCIENCE
Volume28
Issue number6
Early online dateMay 2025
DOIs
StatePublished - 20 Jun 2025

Funding

This study was supported by the grants of National Natural Science Foundation of China (nos. 82372069 and 82072041) , and the Outstanding Youth Foundation of Hubei Province, China (2023AFA107) .

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cancer
  • Health sciences
  • Virology

Indexed by

  • SCIE
  • Scopus

Fingerprint

Dive into the research topics of 'HBV reactivation and its management in HBV-related HCC patients undergoing HAIC-TKI-ICI therapy: A multicenter study'. Together they form a unique fingerprint.

Cite this